SCN5A and long QT syndrome 3: Further experiments on a variety of different LQT3 mutations are therefore warranted to determine whether (1) the effects of empagliflozin on peak-INa are specific to the R1623Q mutation, (2) empagliflozin also inhibits late-INa in LQT3 mutations with different locations in Nav1.5, and (3) genetic models of LQT3 are sensitive to empagliflozin and other SGLT2is.